Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1813964 | 0.85 | ALDH1A1 (0.50) | LMNAALDH1A1MAPTGPR119PDE4B | |
| SCHEMBL4524382 | 0.84 | PDE4B (0.53) | LMNAALDH1A1MAPTPDE4B | |
| SCHEMBL12002916 | 0.84 | GPR119 (0.51) | LMNAALDH1A1MAPTGPR119PDE4B | |
| SCHEMBL2575871 | 0.84 | PDE4B (0.49) | LMNAALDH1A1MAPTPDE4B | |
| SCHEMBL12002938 | 0.84 | ALDH1A1 (0.49) | LMNAALDH1A1MAPTGAAPDE4B | |
| SCHEMBL17631454 | 0.83 | AAK1 (0.46) | GPR119TBK1PDE4B | |
| SCHEMBL3817206 | 0.83 | NR1H2 (0.47) | ALDH1A1GPR119TBK1PDE4B | |
| SCHEMBL17645008 | 0.81 | AAK1 (0.45) | GPR119TBK1PDE4B | |
| SCHEMBL6184027 | 0.79 | ALDH1A1 (0.58) | LMNAALDH1A1MAPTSMN1; SMN2GPR119 | |
| SCHEMBL2277773 | 0.78 | USP30 (0.44) | GPR119TBK1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089397-B1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8049013-B2 | 5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| US-20100069352-A1 | 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| EP-2089397-A1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008076562-A1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL] -2-PHENYL-5H-THIAZ0L0 [5,4-C] PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069352-A1 | 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, HCRTR1 | LMNA 3365/4885ALDH1A1 1275/4885MAPT 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.